qualityassurance
★    

2025-09-25 09:41
(265 d 06:13 ago)

Posting: # 24447
Views: 1,538
 

 Guideline on the requirements for demonstrating Therapeutic equivalence between orally inhaled products (OIP) for asthma [Regulatives / Guidelines]

Post reply
Dear all,

EMA has rcently released Guideline on the requirements for demonstrating Therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD) EMA guideline.

It is stated that This guideline replaces "Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents (CPMP/EWP/4151/00 Rev. 1)”

Based on above statement, can we consider this guideline for development of nasal spray for the treatment of seasonal allergic rhinitis?
Can we demonstrate equivalence through in vitro data only (our formulation is not Q1/Q2 similar)?

Looking forwad for expert opinions.

Regards,
QA
 
UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
180 visitors (0 registered, 180 guests [including 17 identified bots]).
Forum time: 15:55 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5